Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT07275814 is registered in ClinicalTrials.gov with Shanghai Shengdi Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07275814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07275814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Lead sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 17, 2025
Completion date
June 17, 2026
Enrollment
250 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

for contrast-enhanced magnetic resonance imaging (mri) of central nervous system (cns) lesions